LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 226

Search options

  1. Article: Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère.

    Schleich, Florence / Sabbe, Mare / Moermans, Catherine / Louis, Renaud

    Revue medicale de Liege

    2024  Volume 79, Issue 1, Page(s) 60–64

    Abstract: Here we present pharmacological and clinical properties of a new biological targeting TSLP (Thymic Stromal LymphoPoietin). Tezspire® is the name of this targeted treatment which contains 210 mg tezepelumab administered subcutaneously once a month. As ... ...

    Title translation Tezepelumab (Tezspire®) : new biological treatment of severe asthma.
    Abstract Here we present pharmacological and clinical properties of a new biological targeting TSLP (Thymic Stromal LymphoPoietin). Tezspire® is the name of this targeted treatment which contains 210 mg tezepelumab administered subcutaneously once a month. As compared to placebo, tezepelumab reduced exacerbations whatever the baseline blood eosinophil counts, exhaled nitric oxide (FeNO) level and atopic status. The response was higher in patients exhibiting the highest levels of blood eosinophils and FeNO. Tezepelumab also improved pre- bronchodilatation forced expiratory volume in one second, symptomatic control of asthma and quality of life. Tezepelumab proved a broad anti-inflammatory effect by blocking IL-4, IL-13 and IL-5 pathways, inducing a significant reduction in serum total IgE levels, FeNO, blood and sub-mucosal eosinophils, without affecting neutrophil level. Tezepelumab also reduced bronchial hyperresponsiveness and mucus plugs.
    MeSH term(s) Humans ; Quality of Life ; Asthma/drug therapy ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cytokines/metabolism ; Cytokines/therapeutic use
    Chemical Substances tezepelumab (RJ1IW3B4QX) ; Antibodies, Monoclonal, Humanized ; Cytokines
    Language French
    Publishing date 2024-01-15
    Publishing country Belgium
    Document type English Abstract ; Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Le GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2023 : une révision substantielle.

    Ansiaux, Louise / Bonhomme, Olivier / Heinen, Vincent / Schleich, Florence / Louis, Renaud

    Revue medicale de Liege

    2024  Volume 79, Issue 4, Page(s) 235–240

    Abstract: The GOLD is a consensus summarizing current evidence gathered to assess, diagnose and manage patients with chronic obstructive pulmonary disease (COPD). Each year, this GOLD document is enriched with new studies and articles. The year 2023 was special ... ...

    Title translation The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2023 : a substantial revision.
    Abstract The GOLD is a consensus summarizing current evidence gathered to assess, diagnose and manage patients with chronic obstructive pulmonary disease (COPD). Each year, this GOLD document is enriched with new studies and articles. The year 2023 was special because more than 387 new references were added. These new developments have considerably modified the diagnostic and therapeutic approaches to COPD.
    MeSH term(s) Humans ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Pulmonary Disease, Chronic Obstructive/therapy
    Language French
    Publishing date 2024-04-11
    Publishing country Belgium
    Document type English Abstract ; Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Granulocytic Airway Inflammation and Clinical Asthma Outcomes.

    Louis, Renaud E / Schleich, Florence N

    American journal of respiratory and critical care medicine

    2021  Volume 203, Issue 7, Page(s) 797–799

    MeSH term(s) Asthma/drug therapy ; Granulocytes ; Humans ; Inflammation ; Lung ; Sputum
    Language English
    Publishing date 2021-02-19
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202102-0356ED
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Cas clinique. Quand l’éosinophilie n’est pas qu’un marqueur d’asthme...

    Hamdi, Jalal / Heinen, Vincent / Fiévet, Frédéric / El Moussaoui, Majdouline / Louis, Renaud / Schleich, Florence

    Revue medicale de Liege

    2024  Volume 79, Issue 4, Page(s) 208–214

    Abstract: We report the case of a patient who has been hospitalized for dyspnea. Investigations revealed airway obstruction, eosinophilia, elevated IgE and elevated exhaled nitric oxide. Patient improved with oral corticosteroids (OCS). However, the patient ... ...

    Title translation When eosinophilia is not only a marker of asthma ….
    Abstract We report the case of a patient who has been hospitalized for dyspnea. Investigations revealed airway obstruction, eosinophilia, elevated IgE and elevated exhaled nitric oxide. Patient improved with oral corticosteroids (OCS). However, the patient presented two exacerbations requiring OCS during the next twelve months. Chest CT scan revealed two multiloculated parenchymal lesions. Lab test was positive for Echinococcus and Western-Blot confirmed infection with Echinococcus granulosus. Bronchoalveolar lavage confirmed the presence of 6 % eosinophils. Echinococcus granulosis is a zoonotic larval infection caused by a tapeworm larva. Patients with this disease may be asymptomatic for years. Early identification and management, in a multidisciplinary team, are essential and rely mainly on surgical intervention and antiparasitic treatments. This article presents the case of a young patient with pulmonary echinococcosis.
    MeSH term(s) Animals ; Humans ; Eosinophilia/complications ; Asthma/complications ; Asthma/diagnosis ; Eosinophils ; Echinococcus granulosus ; Zoonoses/complications
    Language French
    Publishing date 2024-04-11
    Publishing country Belgium
    Document type Case Reports ; English Abstract
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Dupilumab, Dupixent® :un nouveau traitement pour l’asthme sévère avec un profil «T2 high».

    Louis, Renaud / Sabbe, Mare / Bougard, Nicolas / Frix, Anne-Noëlle / Schleich, Florence

    Revue medicale de Liege

    2024  Volume 79, Issue 4, Page(s) 255–259

    Abstract: Severe asthma often features a T2 high profile regulated by cytokines such as interleukins IL-4, IL-5 and IL-13. Dupilumab (Dupixent®) is humanized monoclonal antibody directed against the α subunit of the receptor for IL-4 and IL-13. Here we summarise ... ...

    Title translation Dupilumab : a new treatment for severe T2 high asthma.
    Abstract Severe asthma often features a T2 high profile regulated by cytokines such as interleukins IL-4, IL-5 and IL-13. Dupilumab (Dupixent®) is humanized monoclonal antibody directed against the α subunit of the receptor for IL-4 and IL-13. Here we summarise the immunogical background of severe asthma which supports the use of dupilumab and the pivotal randomised controlled trials which have established the efficacy of dupilumab in treating people with severe asthma. Dupilumab reduces the exacerbation rate, has corticosteroids sparing effect, provides sustained improvement in expiratory flow rates and improved asthma control and quality of life with a reassuring safety profile. Dupilumab reduces the levels of FeNO values and of serum IgE but not those of circulating eosinophils. We also report on a few real life data with dupilumab supporting its clinical effectiveness.
    MeSH term(s) Humans ; Interleukin-4/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Interleukin-13/therapeutic use ; Quality of Life ; Asthma/drug therapy ; Anti-Asthmatic Agents/pharmacology ; Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized
    Chemical Substances dupilumab (420K487FSG) ; Interleukin-4 (207137-56-2) ; Antibodies, Monoclonal ; Interleukin-13 ; Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized
    Language French
    Publishing date 2024-04-11
    Publishing country Belgium
    Document type English Abstract ; Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Concept de rémission dans l’asthme sévère.

    Vervier, Jeanne / Guissard, Françoise / Henket, Monique / Calmes, Doriane / Wirth, Claudine / Louis, Renaud / Schleich, Florence

    Revue medicale de Liege

    2024  Volume 79, Issue 4, Page(s) 241–247

    Abstract: The use of biotherapies has revolutionized the management of severe asthma. Following a review of asthma pathophysiology, which underpins the development of these new molecules, this article discusses the different types of remission in childhood and ... ...

    Title translation Concept of remission in severe asthma.
    Abstract The use of biotherapies has revolutionized the management of severe asthma. Following a review of asthma pathophysiology, which underpins the development of these new molecules, this article discusses the different types of remission in childhood and adult asthma. The possibilities of achieving remission with each biotherapy and the factors that predict remission will then be developed. Finally, we'll discuss the chances of maintaining good control of the disease after discontinuation of biotherapies, as well as their contribution in terms of systemic and local cortisone sparing.
    MeSH term(s) Adult ; Humans ; Asthma/drug therapy ; Biological Therapy
    Language French
    Publishing date 2024-04-30
    Publishing country Belgium
    Document type Review ; English Abstract ; Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Cytokine-targeted therapies for asthma and COPD.

    Schleich, Florence / Bougard, Nicolas / Moermans, Catherine / Sabbe, Mare / Louis, Renaud

    European respiratory review : an official journal of the European Respiratory Society

    2023  Volume 32, Issue 168

    Abstract: Asthma affects over 300 million people worldwide and its prevalence is increasing. COPD is the third leading cause of death globally. Asthma and COPD are complex inflammatory diseases of the airways in which impaired host defences lead to increased ... ...

    Abstract Asthma affects over 300 million people worldwide and its prevalence is increasing. COPD is the third leading cause of death globally. Asthma and COPD are complex inflammatory diseases of the airways in which impaired host defences lead to increased susceptibility to pathogens, pollutants and allergens. There is a constant interplay between host and the environment. Environmental exposures can alter the lung microbiome and influence the development of sensitisation by disrupting normal immunoregulation. The underlying airway inflammation in severe asthma is heterogeneous, with upregulation of type 2 cytokines in most cases but increased neutrophilic inflammation and activated T-helper 17 mediated immunity in others. COPD may also comprise several different phentoypes that are driven by different molecular mechanisms or endotypes. This disease heterogeneity is affected by comorbidities, treatments and environmental exposures. Recent intervention trials have shed light on the pathways beyond type 2 inflammation that can lead to beneficial outcomes
    MeSH term(s) Humans ; Asthma/diagnosis ; Asthma/drug therapy ; Lung ; Inflammation ; Cytokines ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/metabolism
    Chemical Substances Cytokines
    Language English
    Publishing date 2023-04-19
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 1077620-5
    ISSN 1600-0617 ; 0905-9180
    ISSN (online) 1600-0617
    ISSN 0905-9180
    DOI 10.1183/16000617.0193-2022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3265: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: It needs more than just eosinophils to cause emphysema in COPD.

    Schleich, Florence / Louis, Renaud

    The European respiratory journal

    2019  Volume 53, Issue 5

    MeSH term(s) Emphysema ; Eosinophils ; Humans ; Interleukin-13 ; Leukocyte Count ; Pulmonary Emphysema
    Chemical Substances Interleukin-13
    Language English
    Publishing date 2019-05-30
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.00332-2019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2322: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 292: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: NOVELTY: a landmark study in phenotyping and endotyping chronic obstructive airway diseases in real clinical practice.

    Louis, Renaud / Louis, Gilles / Bonhomme, Olivier

    The European respiratory journal

    2021  Volume 58, Issue 3

    MeSH term(s) Airway Remodeling ; Humans ; Pulmonary Disease, Chronic Obstructive/diagnosis
    Language English
    Publishing date 2021-09-23
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.00627-2021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2322: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 292: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Vaccination antipneumococcique dans les groupes à risque avec comorbidités : recommandations du Conseil Supérieur de la Santé et critères de remboursement.

    Scheen, André / Louis, Renaud / Lancellotti, Patrizio / Jouret, François / Delwaide, Jean / Moutschen, Michel

    Revue medicale de Liege

    2023  Volume 78, Issue 11, Page(s) 665–673

    Abstract: Streptococcus pneumoniae infections cause community-acquired pneumonia and invasive pneumococcal disease such as sepsis and acute meningitis. In the adult population, the risk of severe infections, which can be lethal, is particularly high among people ... ...

    Title translation Pneumococcal vaccination among at-risk groups with comorbidities : guidelines from the "Belgian Superior Health Council" and reimbursement criteria.
    Abstract Streptococcus pneumoniae infections cause community-acquired pneumonia and invasive pneumococcal disease such as sepsis and acute meningitis. In the adult population, the risk of severe infections, which can be lethal, is particularly high among people aged above 65 years and subgroups with comorbidities. Pneumococcal vaccines underwent progressive improvement and a new conjugated vaccine targeting 20 serotypes (PCV20) is now available. The Belgian Superior Health Council has recently reiterated the importance of vaccinating at-risk individuals against S. pneumoniae and now recommends vaccination with PCV20 (Apexxnar®) as the preferred primary vaccination regimen in all at-risk adults. The present article reminds the risk of severe pneumococcal infections among patients with comorbidities, by targeting five of them, chronic respiratory diseases, heart failure, chronic kidney disease, diabetes mellitus and cirrhosis. It emphasizes the too low rate of pneumococcal vaccination in these at-risk subgroups and summarizes the last guidelines of the Belgian Superior Health Council in favor of pneumococcal vaccination in at-risk patients with comorbidities. Finally, it describes the Belgian reimbursement criteria recently granted to people aged 65-85 years with comorbidities.
    MeSH term(s) Adult ; Humans ; Belgium/epidemiology ; Pneumococcal Infections/epidemiology ; Pneumococcal Infections/prevention & control ; Streptococcus pneumoniae ; Vaccination ; Pneumococcal Vaccines ; Vaccines, Conjugate
    Chemical Substances Pneumococcal Vaccines ; Vaccines, Conjugate
    Language French
    Publishing date 2023-11-13
    Publishing country Belgium
    Document type English Abstract ; Journal Article
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top